Integrated Filing — IndAS



General information about company

Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company NECTAR LIFESCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 23-01-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment
Start date and time of board meeting 23-01-2026   15:00:00
End date and time of board meeting 23-01-2026   16:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default by the Company on its loans. The Company has not issued any debt securities.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 0.00 0.00
Other income 66.08 171.09
Total income 66.08 171.09
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 60.95 65.00
(e) Finance costs 3,022.46 3,022.47
(f) Depreciation, depletion and amortisation expense 6.19 25.98
(f) Other Expenses
1 Other Expenses 131.52 152.67
Total other expenses 131.52 152.67
Total expenses 3,221.12 3,266.12
3 Total profit before exceptional items and tax (3,155.04) (3,095.03)
4 Exceptional items 8,815.13 8,815.13
5 Total profit before tax 5,660.09 5,720.10
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (1,102.49) (1,081.52)
9 Total tax expenses (1,102.49) (1,081.52)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,762.58 6,801.62
12 Profit (loss) from discontinued operations before tax (9,657.26) (46,444.93)
13 Tax expense of discontinued operations (4,321.65) (17,146.63)
14 Net profit (loss) from discontinued operation after tax (5,335.61) (29,298.30)
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,426.97 (22,496.68)
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 1,426.97 (22,496.68)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,242.61 2,242.61
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.02 3.03
Diluted earnings (loss) per share from continuing operations 3.02 3.03
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -2.38 -13.06
Diluted earnings (loss) per share from discontinued operations -2.38 -13.06
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.64 -10.03
Diluted earnings (loss) per share from continuing and discontinued operations 0.64 -10.03
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results were reviewed by Audit Committee on January 23, 2026 and approved by the Board of Directors (“Board”) of Nectar Lifesciences Limited (“Company”) in its meeting held on January 23, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter and Nine Months ended on December 31, 2025. 2. The company is exclusively in the pharmaceutical business segment. 3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 4. The Company has one wholly owned subsidiary, namely NECLIFE PT, UNIPESSOAL LDA, which is Inoperative during the period ended on December 31, 2025. 5. Discontinued Operations A.Pharma Business On July 7, 2025, the Company entered into a Business Transfer Agreement (Pharma BTA) for the transfer of its Active Pharmaceutical Ingredients business (located at Unit 1 and Unit 2, Derabassi, Punjab) and Formulation business (located at Unit 6, Baddi, Himachal Pradesh) (Pharma Businesses) to Ceph Lifesciences Private Limited (Ceph) by way of a slump sale on a going concern basis for a total consideration of INR 127,000.00 lakhs. The transfer of the Pharma Businesses was approved by the shareholders of the Company on August 4, 2025. The slump sale was completed on November 10, 2025. Accordingly, after working capital adjustments as per the Pharma BTA, the final consolidated consideration for Pharma BTA has been determined at INR 125,398.55 lakhs. Out of the above amount, the Company has received INR 106,598.55 lakhs up to December 31, 2025, and the balance of INR 18,800.00 lakhs is receivable as at the quarter end. A resultant profit of INR 8,815.13 lakhs (net of current and deferred tax impact of INR 7,522.19 lakhs) arising from the sale of the Pharma Businesses has been recognised under Exceptional Items. B. Menthol Assets Further, the Company entered into an Asset Purchase Agreement (APA) dated July 7, 2025, for the transfer of assets relating to its menthol business (Menthol Assets) to CEPH for a consideration of INR 2,000.00 lakhs. The Menthol Asset transfer was completed on November 10, 2025. The Company has received the full consideration under the APA up to December 31, 2025. C. Capsule Business (EHGC) Further, on December 20, 2025, the Company entered into a Business Transfer Agreement (Capsule BTA) with Capnest Health Care Private Limited (Capnest) for Sale of its business of manufacture, distribution and marketing of Empty Hard Gelatin Capsule (located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh) (Capsule Business) of the Company. The transaction is for a consideration of INR 1,990.00 lakhs along with the takeover of accounts receivable and payables/ creditors by the Capnest, or such other working capital adjustments as specified in the Capsule BTA. The sale is structured as a slump sale on a going concern basis and is subject to approval from the Government of Himachal Pradesh under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA.\ Further, in the unaudited standalone financial results, the net results of Pharma Businesses, Menthol Assets and Capsule Business has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule III to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended December 31, 2025 pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., 30-Sep-25, 31-Dec-24 and 31-Mar-25, have been restated accordingly. Operations relating to the Pharma Business, Assets and Capsule Business in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: INR in lakhs S. No. Particulars Quarter Ended 9 Months Ended Year Ended 31-Dec-25 30-Sep-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 Restated Restated Restated Restated Restated Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Revenue from operations 2,173.55 9,327.02 45,433.44 39,567.08 1,24,106.60 1,66,997.36 2 Other income 1,214.40 2.56 74.98 1,221.64 143.24 336.06 3 Total expenses 13,045.21 36,428.28 44,288.84 87,233.65 1,21,760.27 1,83,581.54 4 Profit before tax (9,657.26) (27,098.70) 1,219.58 (46,444.93) 2,489.57 (16,248.12) 5 Tax expenses (4,321.65) (9,467.90) 458.44 (17,146.63) 929.09 (4,818.42) 6 Net profit after tax (5,335.61) (17,630.80) 761.14 (29,298.30) 1,560.48 (11,429.70) 6.Buy-back of Equity Shares The Board, at its meeting held on December 03, 2025, approved a proposal for the Company to buy back its fully paid-up equity shares (face value of INR 1/- each) at a price of INR 27.00 per share for an aggregate amount of INR 8,100.00 lakhs. The buyback offer comprises the purchase of 3,00,00,000 equity shares, representing approximately 13.38% of the total paid-up equity share capital of the Company as at March 31, 2025. The buyback is proposed to be made from all equity shareholders of the Company, excluding the Promoters and members of the Promoter Group, as on the record date, on a proportionate basis through the “Tender Offer” route, in accordance and consonance with the provisions of the Companies Act, 2013 (Act) and the SEBI (Buy Back of Securities) Regulations, 2018 (Buyback Regulations) (including any statutory modification(s) or re-enactment thereof) and the rules made and circulars issued thereunder. The payment for the buy back has been made by the Company on January 13, 2026 and the 3,00,00,000 equity shares has been extinguished by the National Securities Depository Limited (NSDL) on January 20,2026. All the relevant dates being subsequent to the financial reporting date, no effect of the buy-back has been recognized in the Statement of Profit and Loss for the quarter ended December 31, 2025. 7. Extraordinary and Exceptional items – Refer Note 5.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income